BIOCRYST PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M |
| Cost of revenue | $19.1M | $12.3M | $4.5M | $6.4M | $7.2M |
| Selling, general & administrative | $348.6M | $266.3M | $214.1M | $159.4M | $118.8M |
| Research and development | $166.1M | $174.6M | $216.6M | $253.3M | $208.8M |
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M |
| Interest expense | $78.9M | $98.5M | $108.2M | $99.1M | $59.3M |
| Pretax income | $267.4M | -$87.0M | -$226.2M | -$244.4M | -$181.8M |
| Income tax expense | $3.5M | $1.9M | $310,000 | $2.7M | $2.3M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M |
| Balance Sheet | |||||
| Cash and equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M |
| Current assets | $404.3M | $422.0M | $496.0M | $516.5M | $566.1M |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M |
| Current liabilities | $196.1M | $160.4M | $150.0M | $105.5M | $103.7M |
| Total liabilities | $633.3M | $966.4M | $972.5M | — | — |
| Stockholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M |
| Cash Flow Statement | |||||
| Cash from operations | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M |
| Depreciation and amortization | $1.4M | $1.2M | $1.7M | $1.4M | $777,000 |
| Stock-based compensation | $85.1M | $65.4M | $55.6M | $44.7M | $34.6M |
| Capital expenditure | $2.5M | $1.1M | $2.2M | $1.4M | $2.4M |
| Free cash flow | $344.9M | -$53.1M | -$97.3M | -$163.2M | -$144.5M |
| Impairments | $0 | $0 | $1.5M | $0 | $0 |
Shares outstanding 254.2M · Free float 96.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.